EPCAM: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of EPCAM. The page also collects GeneMedi's different modalities and formats products for EPCAM in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the EPCAM target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]

Target IDGM-T47863
Target NameEPCAM
Gene ID4072,17075,171577,677680,481360,101081794,514039,100053148
Gene Symbol and SynonymsBer-Ep4,BerEp4,CD326,DIAR5,EGP,EGP-2,EGP314,EGP40,Ep-CAM,EPCAM,EpCAM1,ESA,GA733-2,gp40,HNPCC8,KS1/4,KSA,Ly74,LYNCH8,M4S1,MIC18,MK-1,MOC-31,Tacsd1,TACSTD1,TROP1
Uniprot AccessionP16422,O55159,Q1WER1,Q3T0L5
Uniprot Entry NameEPCAM_HUMAN,EPCAM_MACMU,EPCAM_RAT,EPCAM_BOVIN
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, Immuno-oncology Target, INN Index
DiseaseOvary Cancer
Gene EnsemblENSG00000119888
Target ClassificationCheckpoint-Immuno Oncology


Pre-made EPCAM-specific INN-index biosimilar (antibody&conjugates)

Anti-EPCAM therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatDetail
GMP-Bios-ab-107Pre-Made Citatuzumab biosimilar, Fab Fusion, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodyCitatuzumabEPCAMFab FusionDetail
GMP-Bios-INN-781Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganincitatuzumab bogatoxEPCAMFusion ProteinDetail
GMP-Bios-INN-772Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodycatumaxomabCD3E;EPCAMBispecificDetail
GMP-Bios-ab-408Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodyOportuzumabEPCAMscFvDetail
GMP-Bios-INN-719Pre-Made Adecatumumab Biosimilar, Whole Mab, Anti-Epcam Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodyadecatumumabEPCAMWhole? mAbDetail
GMP-Bios-ab-165Pre-Made Edrecolomab biosimilar, Whole mAb, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodyEdrecolomabEPCAMWhole mAbDetail
GMP-Bios-INN-939Pre-Made Oportuzumab Monatox biosimilar, Fusion Protein, Oportuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin Aoportuzumab monatoxEPCAMFusion ProteinDetail
GMP-Bios-ab-528Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibodySolitomabEPCAM;CD3EBispecific scFvDetail
GMP-Bios-INN-1035Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153tucotuzumab celmoleukinEPCAMFusion ProteinDetail

Click to check more INN-indexed antibody & protein biosimilar



Pre-made anti-EPCAM inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-EPCAM benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-EPCAM mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-EPCAM monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional Antibody, Therapeutics Target antibodyDetail



Multi-species EPCAM/ DIAR5/ EGP-2 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EPCAM VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
EPCAM VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing



Pre-made EPCAM viral vector in GM Promise-ORFTM

Cat No.Products nameNM IDSpeciesTypeDetail
pGMLV000875human EPCAM Lentivirus plasmidNM_002354.2HumanLentivirus plasmidDetail
vGMAAV000236human EPCAM AAV particleNM_002354HumanAAV particleDetail
pGMLV000293human EPCAM Lentivirus plasmidNM_002354.2HumanLentivirus plasmidDetail
vGMLV000293human EPCAM Lentivirus particleNM_002354.2HumanLentivirus particleDetail
vGMLV000875human EPCAM Lentivirus particleNM_002354.2HumanLentivirus particleDetail
pGMAAV000236human EPCAM AAV plasmidNM_002354HumanAAV plasmidDetail
pGMAP000558Human EPCAM Adenovirus plasmidBC014785HumanAdenovirus plasmidDetail
pGMAAV000214human EpCAM AAV plasmidNM_002354HumanAAV plasmidDetail
vGMAP000558Human EPCAM Adenovirus particleBC014785HumanAdenovirus particleDetail
vGMAAV000214human EpCAM AAV particleNM_002354HumanAAV particleDetail
pGMLPm002282mouse Epcam Lentivirus plasmidNM_008532MouseLentivirus plasmidDetail
vGMLPm002282mouse Epcam Lentivirus particleNM_008532MouseLentivirus particleDetail

About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<